Actively Recruiting
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Led by Novartis Pharmaceuticals · Updated on 2026-04-21
20
Participants Needed
22
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease
CONDITIONS
Official Title
A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 1 year or older with a diagnosis of Still's Disease
- Active disease defined by elevated CRP or ferritin levels above the upper limit of normal
- Presence of at least one of the following: fever (≥ 38°C) attributed to Still's Disease, rash attributed to Still's Disease, arthritis in multiple joints per ACP criteria, serositis, or macrophage activation syndrome activity as defined by ferritin and other biomarkers
- Need for glucocorticoid treatment (prednisone or equivalent)
You will not qualify if you...
- Patients outside the required weight range
- Ongoing or previous treatment with immunomodulatory drugs (except limited MAS825 use through managed access)
- Glucocorticoid dose exceeding a set limit
- Any significant medical condition posing unacceptable risk for MAS825 therapy
- History of ongoing, chronic, or recurrent infections such as HIV, TB, HCV, or HBV, or signs of active infections
- Receipt of live vaccinations within a specified time before MAS825 treatment
- History of malignancies including post-transplant lymphoproliferative disorder within a set number of years
- History of hypersensitivity to MAS825, related drugs, or any excipients
- Pregnant or breastfeeding women
- Women of child-bearing potential who do not agree to use required contraception
- Other protocol-defined inclusion/exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 22 locations
1
Cincinnati Childrens Hospital
Cincinnati, Ohio, United States, 45229
Actively Recruiting
2
Legacy Emanuel Research Hosp Portland
Portland, Oregon, United States, 97232
Actively Recruiting
3
Novartis Investigative Site
Montreal, Quebec, Canada, H3T 1C5
Actively Recruiting
4
Novartis Investigative Site
Montreal, Quebec, Canada, H4A 3J1
Actively Recruiting
5
Novartis Investigative Site
Bordeaux, France, 33076
Actively Recruiting
6
Novartis Investigative Site
Bron, France, 69677
Actively Recruiting
7
Novartis Investigative Site
Le Kremlin-Bicêtre, France, 94275
Actively Recruiting
8
Novartis Investigative Site
Lille, France, 59037
Actively Recruiting
9
Novartis Investigative Site
Paris, France, 75015
Actively Recruiting
10
Novartis Investigative Site
Paris, France, 75970
Actively Recruiting
11
Novartis Investigative Site
Sankt Augustin, North Rhine-Westphalia, Germany, 53757
Actively Recruiting
12
Novartis Investigative Site
Heidelberg, Germany, 69120
Actively Recruiting
13
Novartis Investigative Site
Münster, Germany, 48149
Actively Recruiting
14
Novartis Investigative Site
Florence, FI, Italy, 50139
Actively Recruiting
15
Novartis Investigative Site
Genova, GE, Italy, 16147
Actively Recruiting
16
Novartis Investigative Site
Roma, RM, Italy, 00165
Actively Recruiting
17
Novartis Investigative Site
Utrecht, Netherlands, 3584 CX
Actively Recruiting
18
Novartis Investigative Site
Esplugues, Barcelona, Spain, 08950
Actively Recruiting
19
Novartis Investigative Site
Madrid, Spain, 28046
Actively Recruiting
20
Novartis Investigative Site
Valencia, Spain, 46026
Actively Recruiting
21
Novartis Investigative Site
Istanbul, Fatih, Turkey (Türkiye), 34098
Actively Recruiting
22
Novartis Investigative Site
Ankara, Sihhiye-Altindag, Turkey (Türkiye), 06230
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here